Furthermore, tirzepatide has demonstrated cardioprotective effects against sepsis-induced cardiomyopathy, evidenced by reduced APD and QTc, through targeting the TLR4/NF-kB/NLRP3 pathway [195]. This evidence concerns the gene TLR4 and cardiomyopathy.